EU FP7 research funding for an orphan drug (Orfadin®) and vaccine (Hep C) development: a success and a failure?

EU FP7 research funding for an orphan drug (Orfadin®) and vaccine (Hep C) development: a success and a failure?

Background We considered the extent of the contribution of publicly funded research to the late-stage clinical development of pharmaceuticals and medicinal products, based on the European Commission (EC) FP7 research funding programme. Using two EC FP7-HEALTH case study examples—representing two typ...

Full description

Bibliographic Details
Main Authors: L. Schmidt, O. Sehic, C. Wild
Format: Article
Language:English
Published: Taylor & Francis Group 2021-12-01
Series:Journal of Pharmaceutical Policy and Practice
Subjects:
research funding
public funding
return on investment
late-stage clinical development
Online Access:http://dx.doi.org/10.1186/s40545-021-00317-8

Similar Items

Similar Items